» Articles » PMID: 15118911

Stability and Inactivation of SARS Coronavirus

Overview
Date 2004 May 1
PMID 15118911
Citations 283
Authors
Affiliations
Soon will be listed here.
Abstract

The SARS-coronavirus (SARS-CoV) is a newly emerged, highly pathogenic agent that caused over 8,000 human infections with nearly 800 deaths between November 2002 and September 2003. While direct person-to-person transmission via respiratory droplets accounted for most cases, other modes have not been ruled out. Faecal shedding is common and prolonged and has caused an outbreak in Hong Kong. We studied the stability of SARS-CoV under different conditions, both in suspension and dried on surfaces, in comparison with other human-pathogenic viruses, including human coronavirus HCoV-229E. In suspension, HCoV-229E gradually lost its infectivity completely while SARS-CoV retained its infectivity for up to 9 days; in the dried state, survival times were 24 h versus 6 days. Thermal inactivation at 56 degrees C was highly effective in the absence of protein, reducing the virus titre to below detectability; however, the addition of 20% protein exerted a protective effect resulting in residual infectivity. If protein-containing solutions are to be inactivated, heat treatment at 60 degrees C for at least 30 min must be used. Different fixation procedures, e.g. for the preparation of immunofluorescence slides, as well as chemical means of virus inactivation commonly used in hospital and laboratory settings were generally found to be effective. Our investigations confirm that it is possible to care for SARS patients and to conduct laboratory scientific studies on SARS-CoV safely. Nevertheless, the agents tenacity is considerably higher than that of HCoV-229E, and should SARS re-emerge, increased efforts need to be devoted to questions of environmental hygiene.

Citing Articles

Stability and infectivity of enteroviruses on dry surfaces: Potential for indirect transmission control.

Sittikul P, Sriburin P, Rattanamahaphoom J, Nuprasert W, Thammasonthijarern N, Thaipadungpanit J Biosaf Health. 2025; 5(6):339-345.

PMID: 40078746 PMC: 11895008. DOI: 10.1016/j.bsheal.2023.07.001.


How long do bacteria, fungi, protozoa, and viruses retain their replication capacity on inanimate surfaces? A systematic review examining environmental resilience versus healthcare-associated infection risk by "fomite-borne risk assessment".

Kramer A, Lexow F, Bludau A, Koster A, Misailovski M, Seifert U Clin Microbiol Rev. 2024; 37(4):e0018623.

PMID: 39388143 PMC: 11640306. DOI: 10.1128/cmr.00186-23.


Design of Fragrance Formulations with Antiviral Activity Using Bayesian Optimization.

Zhang F, Hirama Y, Onishi S, Mori T, Ono N, Kanaya S Microorganisms. 2024; 12(8).

PMID: 39203410 PMC: 11356527. DOI: 10.3390/microorganisms12081568.


Laboratory studies on the infectivity of human respiratory viruses: Experimental conditions, detections, and resistance to the atmospheric environment.

Hu Y, Peng S, Su B, Wang T, Lin J, Sun W Fundam Res. 2024; 4(3):471-483.

PMID: 38933192 PMC: 11197496. DOI: 10.1016/j.fmre.2023.12.017.


Tree Species-Dependent Inactivation of Coronaviruses and Enteroviruses on Solid Wood Surfaces.

Shroff S, Peramaki A, Vaisanen A, Pasanen P, Gronlund K, Nissinen V ACS Appl Mater Interfaces. 2024; 16(23):29621-29633.

PMID: 38806169 PMC: 11181278. DOI: 10.1021/acsami.4c02156.


References
1.
Liang W, Zhu Z, Guo J, Liu Z, Zhou W, Chin D . Severe acute respiratory syndrome, Beijing, 2003. Emerg Infect Dis. 2004; 10(1):25-31. PMC: 3092360. DOI: 10.3201/eid1001.030553. View

2.
Snijder E, Bredenbeek P, Dobbe J, Thiel V, Ziebuhr J, Poon L . Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol. 2003; 331(5):991-1004. PMC: 7159028. DOI: 10.1016/s0022-2836(03)00865-9. View

3.
Peiris J, Chu C, Cheng V, Chan K, Hung I, Poon L . Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003; 361(9371):1767-72. PMC: 7112410. DOI: 10.1016/s0140-6736(03)13412-5. View

4.
Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr H . Treatment of SARS with human interferons. Lancet. 2003; 362(9380):293-4. PMC: 7112413. DOI: 10.1016/s0140-6736(03)13973-6. View

5.
Poutanen S, Low D, Henry B, Finkelstein S, Rose D, Green K . Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003; 348(20):1995-2005. DOI: 10.1056/NEJMoa030634. View